KL-A289

N/A

Report date: 2022/06/13 11:22:34

Base Information

Drug NameKL-A289
Drug Alias NameKL-A289
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionLymphocyte activation gene 3 protein inhibitors
TargetsLymphocyte activation gene 3 protein
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSichuan Kelun-Biotech Biopharmaceutical Co LtdAnyuan Pharmaceutical Technology (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSichuan Kelun-Biotech Biopharmaceutical Co LtdAnyuan Pharmaceutical Technology (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A